Ownership and insider activity for CRISPR Therapeutics AG (CRSP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Price
| Price | $52.21 |
| Market Cap | $5.0B |
| Exchange | NASDAQ |
| Country | CH |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $315.5M | $239.8M | $456.6M | $943.8M | $1.17B | $923.0M | $211.9M | $389.5M | $298.3M | $355.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | $521.7M | $1.46B | $1.60B | $1.30B | $1.61B | $1.63B |
| Receivables | $3.2M | $2.6M | $88000 | $99000 | $10.8M | $305000 | 0 | $200.0M | $25.0M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $320.2M | $248.4M | $466.4M | $987.5M | $1.72B | $2.42B | $1.85B | $1.91B | $1.94B | $1.99B |
| Property, Plant & Equipment | $21.0M | $18.9M | $18.5M | $72.8M | $93.0M | $312.0M | $320.6M | $305.9M | $277.6M | $247.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $399000 | $344000 | $289000 | $235000 | $180000 | $125000 | $71000 | $16000 | 0 | 0 |
| Total Assets | $345.0M | $271.3M | $489.0M | $1.07B | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B | $2.27B |
| Accounts Payable | $4.6M | $1.6M | $5.1M | $5.9M | $9.1M | $14.8M | $27.4M | $38.1M | $14.7M | $11.1M |
| Short-term Debt | 0 | 0 | 0 | $8.5M | $11.4M | $12.2M | $15.8M | $15.6M | $17.3M | $18.6M |
| Total Current Liabilities | $22.0M | $14.5M | $27.7M | $57.1M | $94.3M | $119.9M | $121.1M | $108.8M | $87.8M | $149.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $188.2M |
| Total Liabilities | $112.1M | $83.5M | $96.8M | $127.3M | $163.7M | $352.4M | $367.6M | $346.8M | $310.0M | $343.4M |
| Retained Earnings | -$57.1M | -$125.4M | -$291.6M | -$224.7M | -$573.6M | -$195.9M | -$846.1M | -$999.7M | -$1.37B | -$1.95B |
| Total Equity | $232.8M | $187.8M | $392.2M | $939.4M | $1.66B | $2.40B | $1.88B | $1.88B | $1.93B | $1.92B |
| Total Debt | 0 | 0 | 0 | $52.5M | $61.4M | $225.0M | $244.0M | $238.6M | $223.7M | $394.9M |
| Net Debt | -$315.5M | -$239.8M | -$456.6M | -$891.2M | -$1.63B | -$2.15B | -$1.57B | -$1.46B | -$1.68B | -$1.58B |
| Working Capital | $298.2M | $233.9M | $438.6M | $930.4M | $1.62B | $2.30B | $1.73B | $1.80B | $1.85B | $1.84B |
Financial Health
| Debt / Equity | 0.45 |
| Current Ratio | 17.85 |
Profitability
| Gross Margin | -1534.39% |
| Operating Margin | -3971.53% |
| Net Margin | -3368.72% |
Related companies: ACLX · AKRO · ARWR · CYTK · KRYS · MTSR · NUVL
Explore sector: Healthcare · Biotechnology
More sections of CRSP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks